DexCom Inc. (NASDAQ: DXCM) announced results from the CONNECT randomized controlled trial showing its G7 continuous glucose monitor led to a statistically significant reduction in A1C levels among people with type 2 diabetes not using insulin. The results were presented at the American Diabetes Association's Scientific Sessions in New Orleans.

The study included 283 participants across 22 primary care practices in the United States, with 265 completing the 26-week trial. Participants were randomly assigned to use either the Dexcom G7 or traditional blood glucose monitoring.

Participants using the Dexcom G7 experienced an average 1.6% A1C reduction from a baseline mean of 8.8%, representing a 0.9% greater reduction compared to the control group. Among participants with initial A1C levels above 10%, those using the G7 saw a 3.1% reduction, or 2.1% greater than the control group.

The study found 68% of G7 users reached A1C levels below 7.5% at 26 weeks, while 46% achieved levels below 7.0%. Time spent in the target glucose range of 70 to 180 mg/dL increased by five hours per day for G7 users compared to the control group, reaching 62% versus 41% at study completion.

The glucose monitor showed additional benefits when combined with diabetes medications including metformin, GLP-1 receptor agonists, and SGLT2 inhibitors. Among GLP-1 users, the G7 group achieved a 1.4% A1C reduction compared to 0.2% in the control group.

"The CONNECT study released today is the first and only level A evidence demonstrating strong benefit of CGM for the Type 2 non-insulin using population," said Roy Beck, medical director of the JAEB Center for Health Research and senior author of the study.

A six-month extension phase is currently underway to provide data on sustained benefits up to 12 months.